Venezuela -
español -
Instituto Nacional de Higiene
viread 300 mg tabletas recubiertas
laboratorio eicopen, c.a. - tenofovir disoproxil fumarato - tabletas recubiertas - 300 mg
Venezuela -
español -
Instituto Nacional de Higiene
macugen 0,3 mg /90 ul solucion inyectable
pfizer venezuela, s.a. - pegaptanib sodico - solucion inyectable - 0.3mg/90ul
Argentina -
español -
ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
ambisome
gador s.a. - anfotericina - inyectable liofilizado - anfotericina b (en liposomas) 50.0000000 mg / frasco ampolla
Argentina -
español -
ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
emtriva
gador s.a. - emtricitabina - capsulas - emtricitabina 200 mg / cap
Venezuela -
español -
Instituto Nacional de Higiene
tamiflu 75 mg capsulas
productos roche, s.a. - oseltamivir - capsulas - 75 mg
Unión Europea -
español -
EMA (European Medicines Agency)
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agentes antineoplásicos - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
Perú -
español -
DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)
epclusa® 400 mg/100 mg comprimido recubierto
logistics business services s.a.c. - droguerÍa - comprimido recubierto - por comprimido - - sofosbuvir y velpatasvir
Venezuela -
español -
Instituto Nacional de Higiene
harvoni 90 mg - 400 mg comprimidos recubiertos
laboratorio eicopen c.a. - ledipasvir - sofosbuvir - comprimidos recubiertos - 90 mg - 400 mg
Venezuela -
español -
Instituto Nacional de Higiene
sovaldi 400 mg tabletas recubiertas
laboratorio eicopen c.a. - sofosbuvir - tabletas recubiertas - 400 mg
Unión Europea -
español -
EMA (European Medicines Agency)
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - linfoma, célula del manto - agentes antineoplásicos - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).